Exenatide, a glucagon-like peptide-1 (GLP-1) receptoragonist antidiabetic drug, has the capacity to overcome insulin resistance andattenuate hepatic steatosis but the specific underlying mechanism is unclear.This study was designed to investigate the underlying molecular mechanisms ofexenatide therapy on NAFLD. The gene discussed is GCG; the disease is metabolic dysfunction-associated steatotic liver disease.